依托泊苷胶囊联合沙利度胺维持治疗广泛期小细胞肺癌效果观察  

Efficacy of etoposide plus thalidomide for maintenance treatment of extensive small cell lung cancer

作　　者：刘萍[1] 

机构地区：[1]郑州大学第二附属医院肿瘤科,郑州450014

出　　处：《郑州大学学报（医学版）》2013年第3期401-403,共3页Journal of Zhengzhou University(Medical Sciences)

摘　　要：目的:观察依托泊苷胶囊联合沙利度胺用于广泛期小细胞肺癌(ED-SCLC)维持治疗的效果。方法:90例ED-SCLC患者接受6周期的顺铂联合依托泊苷(EP)方案化疗,病情控制。然后分为观察组45例和对照组45例。观察组给予依托泊苷胶囊100mg/d,口服,第1～10天,3周为1个周期;沙利度胺100mg/d,连续睡前顿服。2组每2个月复查直至疾病进展。结果:2组Kaplan-Meier生存曲线差异有统计学意义(χ2=11.653,P=0.001)。观察组中位无进展生存期为5.6个月(95%CI=4.8～6.4个月),对照组为4.2个月(95%CI=3.7～4.7个月),观察组中位无进展生存期较对照组延长了1.4个月。观察组不良反应主要为骨髓抑制、消化道反应、嗜睡及便秘,多为轻度反应,经对症治疗后缓解。结论:依托泊苷胶囊联合沙利度胺用于ED-SCLC的维持治疗效果较好。Aim ： To observe the clinical efficacy of etoposide plus thalidomide fbr maintenance treatment of extensive small cell lung cancer （ED-SCLC）. Methods： A total of 90 patients diagnosed as ED-SCLC received 6 cycles of standard chemotherapy,and obtained disease control. Then they were divided into two groups and 45 cases in each group. Treatment group received etoposide plus thalidomide for maintenance treatment（ etoposide 100 mg/d, per os,Day 1 -10, every 21 days was a cycle; thalidomide 100 rag/d, per os, one single dose before sleep）. The control group did not receive any in- tervention. Regular observations and follow-up were performed in both groups. Results： The Kaplan-Meier survival curves of the two groups were significantly different（x2 = 11. 653, P = 0. 001 ）. The median progression-free survival for treatment group and control group was 5.6 months （95% CI = 4.8 - 6.4 months） and 4.2 months （ 95 % CI= 3.7 - 4.7 months）. The side effects of treatment group included bone marrow suppression, gastrointestinal reactions, sleepiness and constipa- tion, which relieved after drug withdrawal and symptomatic support therapy. Conclusion： Etoposide plus thalidomide for maintenance treatment of ED-SCLC have better effect.

关 键 词：小细胞肺癌 依托泊苷 沙利度胺 维持治疗 

分 类 号：R734.2[医药卫生—肿瘤]